Bio Rad Laboratories Stock Fundamentals
| BIO Stock | USD 325.58 1.89 0.58% |
Bio Rad Laboratories fundamentals help investors to digest information that contributes to Bio Rad's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Rad's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Rad stock.
At this time, Bio Rad's Net Interest Income is very stable compared to the past year. Bio | Select Account or Indicator |
Bio Rad Laboratories Company Operating Margin Analysis
Bio Rad's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Bio Rad Operating Margin | 0.1 % |
Most of Bio Rad's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Rad Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Bio Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Bio Rad Laboratories has an Operating Margin of 0.0994%. This is 100.28% lower than that of the Life Sciences Tools & Services sector and 100.25% lower than that of the Health Care industry. The operating margin for all United States stocks is 101.8% lower than that of the firm.
Bio Rad Laboratories Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio Rad's current stock value. Our valuation model uses many indicators to compare Bio Rad value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Rad competition to find correlations between indicators driving Bio Rad's intrinsic value. More Info.Bio Rad Laboratories is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Bio Rad's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Rad's earnings, one of the primary drivers of an investment's value.Bio Rad's Earnings Breakdown by Geography
Bio Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Rad's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Rad could also be used in its relative valuation, which is a method of valuing Bio Rad by comparing valuation metrics of similar companies.Bio Rad is currently under evaluation in operating margin category among its peers.
Bio Rad ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Rad's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Rad's managers, analysts, and investors.Environmental | Governance | Social |
Bio Fundamentals
| Return On Equity | -0.0979 | ||||
| Return On Asset | 0.0186 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.1 % | ||||
| Current Valuation | 8.88 B | ||||
| Shares Outstanding | 22.92 M | ||||
| Shares Owned By Insiders | 15.57 % | ||||
| Shares Owned By Institutions | 79.90 % | ||||
| Number Of Shares Shorted | 651.7 K | ||||
| Price To Earning | 2.90 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 3.55 X | ||||
| Revenue | 2.67 B | ||||
| Gross Profit | 1.57 B | ||||
| EBITDA | (608.26 M) | ||||
| Net Income | (637.32 M) | ||||
| Cash And Equivalents | 434.21 M | ||||
| Cash Per Share | 62.03 X | ||||
| Total Debt | 1.41 B | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.50 X | ||||
| Book Value Per Share | 267.46 X | ||||
| Cash Flow From Operations | 374.94 M | ||||
| Short Ratio | 3.36 X | ||||
| Earnings Per Share | (28.06) X | ||||
| Price To Earnings To Growth | 1.19 X | ||||
| Target Price | 402.33 | ||||
| Number Of Employees | 7.7 K | ||||
| Beta | 0.94 | ||||
| Market Capitalization | 9.17 B | ||||
| Total Asset | 12.3 B | ||||
| Retained Earnings | 9.26 B | ||||
| Working Capital | 2.53 B | ||||
| Current Asset | 466.61 M | ||||
| Current Liabilities | 208.93 M | ||||
| Net Asset | 12.3 B |
About Bio Rad Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Rad Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Rad using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Rad Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 35.8 B | 37.5 B | |
| Total Revenue | 2.7 B | 1.4 B | |
| Cost Of Revenue | 1.2 B | 1.3 B | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.42 | 0.43 | |
| Research And Ddevelopement To Revenue | 0.08 | 0.10 | |
| Capex To Revenue | 0.06 | 0.07 | |
| Revenue Per Share | 91.45 | 96.03 | |
| Ebit Per Revenue | 0.14 | 0.08 |
Pair Trading with Bio Rad
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bio Rad position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Rad will appreciate offsetting losses from the drop in the long position's value.Moving against Bio Stock
| 0.46 | FBRX | Forte Biosciences Trending | PairCorr |
| 0.42 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.42 | VCNX | Vaccinex | PairCorr |
The ability to find closely correlated positions to Bio Rad could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bio Rad when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bio Rad - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bio Rad Laboratories to buy it.
The correlation of Bio Rad is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bio Rad moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bio Rad Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bio Rad can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bio Rad Piotroski F Score and Bio Rad Altman Z Score analysis. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.412 | Earnings Share (28.06) | Revenue Per Share 90.815 | Quarterly Revenue Growth 0.028 | Return On Assets 0.0186 |
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.